Mindset Pharma and Canada’s top psychiatric research hospital, CAMH, have entered into a collaboration to build the molecular profile of MSP-1014 compared to psilocybin.
The US food and Drugs Administration (FDA) has given approval for MYCO-001 in a recent Investigational New Drug (IND) application, which will now be used in...
Ohio State University is launching The Center for Psychedelic Drug Research and Education (CPDRE).
Enosis Therapeutics has collaborated with Swinburne University and the Psychedelic Society of Belgium to carry out the study – finding that the use of virtual reality...
A new study has revealed how ketamine works, which scientists say paves the way toward the development of safe, effective treatments for depression.
Cybin has confirmed it has received approval for its Phase 1/2a trial evaluating its proprietary deuterated psilocybin analogue for the treatment of Major Depressive Disorder (MDD).
The first patient has been dosed in HMNC and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study.
A new study from Northwestern Medicine has identified for the first time how ketamine works so quickly, and how it might be adapted for use as...
Awakn Life Sciences will be carrying out a follow-on behavioural study to focus on gambling disorder following its recent successful pilot study and patent filing.
Biopharma firm Ceruvia Lifesciences is to carry out a clinical trial of synthetic psilocybin as a potential treatment for obsessive-compulsive disorder (OCD).